# Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

> **NCT03492138** · PHASE1,PHASE2 · TERMINATED · sponsor: **Ajai Chari** · enrollment: 5 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** ONC201
- **DRUG:** Ixazomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03492138
- **Lead sponsor:** Ajai Chari
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-26
- **Primary completion:** 2020-01-14
- **Final completion:** 2020-01-14
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Low enrollment
- **Last updated:** 2020-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03492138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03492138, "Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03492138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*